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Current treatments for clear cell renal cell cancer (ccRCC) are insufficient because two-thirds
of patients with metastases progress within two years. Here we report the identification and
characterization of a cancer stem cell (CSC) population in ccRCC. CSCs are quantitatively
correlated with tumor aggressiveness and metastasis. Transcriptional profiling and single cell
sequencing reveal that these CSCs exhibit an activation of WNT and NOTCH signaling. A
significant obstacle to the development of rational treatments has been the discrepancy
between model systems and the in vivo situation of patients. To address this, we use CSCs to
establish non-adherent sphere cultures, 3D tumor organoids, and xenografts. Treatment with
WNT and NOTCH inhibitors blocks the proliferation and self-renewal of CSCs in sphere
cultures and organoids, and impairs tumor growth in patient-derived xenografts in mice.
These findings suggest that our approach is a promising route towards the development of
personalized treatments for individual patients.
https://doi.org/10.1038/s41467-020-14700-7 OPEN
1 Cancer Research Program, Max Delbrueck Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany. 2 Berlin Institute of Health
(BIH), Berlin, Germany. 3 Department of Urology, Charité-University Medicine, Berlin, Germany. 4 Berlin Institute for Urologic Research, Berlin, Germany.
5 Experimental Pharmacology and Oncology GmbH (EPO), Berlin, Germany. 6 Electron Microscopy Core Facility, Max Delbrueck Center for Molecular
Medicine (MDC) in the Helmholtz Association, Berlin, Germany. 7 Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrueck Center for Molecular
Medicine (MDC) in the Helmholtz Association, Berlin, Germany. 8 Department of Pathology, Charité-University Medicine, Berlin, Germany. 9 Department of
Biology, Southern University of Science and Technology, Shenzhen, China. ✉email: wbirch@mdc-berlin.de
NATURE COMMUNICATIONS |          (2020) 11:929 | https://doi.org/10.1038/s41467-020-14700-7 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Kidney cancer is the twelfth most common malignancy inthe western world, and clear cell renal carcinoma (ccRCC,also called KIRC) is its most common form, affecting
70–80% of patients1. Currently the 5-year survival rate of loca-
lized ccRCC lies at 65%, but it drops to 10–20% once the cancer
has metastasized1. Large scale sequencing has pointed to loss of
the short arm of chromosome 3 and mutations of the Von Hippel
Lindau (VHL) gene as the main drivers of ccRCC. Mutations of
PBRM1, SETD2, BAP1 are found at lower rates2,3.
The heterogeneity observed in kidney tumors has been an
obstacle to successful treatment and might be a major contributor
to relapse4. Significant improvements in post-surgical treatment
have been made in the last two decades: inhibitors of multiple
tyrosine kinases, of mTOR or monoclonal antibodies against
VEGF5,6. Sequential treatments with these inhibitors improve
patient outcomes; nevertheless, within 2 years most tumors
progress. A more recent approach enhances immune responses to
kidney tumors through checkpoint inhibitors which block PD-1
or CTLA-4 on T-cells7, with long-lasting effects for a subset of
patients. Ultimately, improving the long-term prognosis ccRCC
will require personalized treatment strategies specific to the
biology of each tumor.
CSCs have been characterized in many cancers and implicated
in resistance to treatment, tumor recurrence, and metastatic
spread; the situation in kidney cancer has been unclear8–10.
Organoid cultures, grown from stem cells in the presence of
specific growth factor cocktails, have been derived from a range of
tissues and are crucial models in the investigation and treatment
of a range of cancers11. Colon cancer organoids are being used to
study the effects of pathway inhibitors and anti-cancer drugs12.
Yet organoids derived from kidney tumors have only recently
been described; here we report a well-characterized organoid
model from human primary ccRCCs.
In addition, patient-derived xenografts (PDXs) derived
through transplantations of cells and disease tissues into
immune-compromised mice have been used as models to study
renal carcinogenesis13,14. The fidelity that is maintained through
re-passaging makes it possible to produce animals whose tumors
replicate that of an individual patient and can be used to search
for effective treatments.
In combination, PDX and organoids have surpassed the
restrictions of working solely in immortal cell lines and animal
models and permit studying response to therapies in individual
tumors. Based on the behavior of any of these models, robust
predictions about likely outcomes in patients can be made.
We here develop procedures to isolate CSCs from ccRCCs and
analyze them through expression profiling and single-cell
sequencing. We use CSCs from the tumors to produce three
model systems—non-attached sphere cultures, 3D organoids, and
PDX tumors—to overcome the limitations imposed by single
model systems. We treat each model with small molecule inhi-
bitors that target WNT and NOTCH at different stages. This
combined approach may be a promising route toward the
development of personalized treatments for individual patients
leading to early phase clinical trials.
Results
Frequency of CSCs correlates with aggressiveness of ccRCC.
We isolated single cells from patient ccRCC tissues (labeled
ccRCC1, 2 etc.) obtained during surgery (see Supplementary
Table 1 for the characterization of patients) and investigated cell
surface markers on their own and in combination using FACS,
aiming to identify a ccRCC cell stem cell population. The selected
surface markers have been previously identified as stem cell
markers in the kidney (i.e. CD24, CD29, CD133)15, cancer stem
cell markers in other malignancies (CD24, CD29, Epcam, CD44,
MET, CD90, ALDH1A1 activity)16–21, and in the kidney (CD133,
CD24, CD105, CXCR4)8,9,15,22. FACS revealed a distinct popu-
lation of CXCR4+MET+ cells in patient’s tumor which could be
further sorted into CD44+ and CD44− cells (Fig. 1a and Sup-
plementary Fig. 1a). The chemokine receptor CXCR4 and the
receptor tyrosine kinase MET had been associated with ccRCC in
previous studies23–26. We found that CD44, a frequent marker of
CSCs8,9,27, can further refine this population. CXCR4+
MET+CD44+ cells amounted to 2.2% of total tumor cells on
average (range: 0.2–11%). We seeded FAC-sorted cells in
decreasing numbers to test their sphere-forming abilities, as a
read-out for the self-renewing capacity. Triple-positive cells (red)
were able to form spheres at cell numbers ten-fold less than
CXCR4−MET−CD44− cells (black) (Fig. 1b). Spheres formed by
triple-positive cells were also larger than spheres generated from
negative cells (Fig. 1c, d).
We used the same procedure to analyze the remaining markers:
CD24, CD29, CD105, CD133, CD90, and ALDH1A1. CD24 and
CD29 were detected almost ubiquitously on ccRCC cells
(Supplementary Fig. 1b) and were therefore excluded. The other
markers failed to enrich for self-renewing cells (Supplementary
Fig. 1c–f). Epcam, a marker for epithelial and carcinoma cells
used in other solid malignancies28,29, was detected at low levels in
ccRCC, as determined both by FACS and immunofluorescence
(Supplementary Fig. 1g, h), and was likewise excluded.
To examine whether the frequency of CXCR4+MET+CD44+
cells correlated with the aggressiveness of the tumors, we used
FACS to isolate cells from the primary ccRCC tumors of 41
patients selected from the 55 in Supplementary Table 1. CXCR4+
MET+CD44+ cells were highly enriched in tumors with a high
pathological stage (Fig. 1e), a high Fuhrman grade (Fig. 1f)30,
venous and lymphatic invasion (Fig. 1g, h) and distant metastases
(Fig. 1i) at the time of surgery. Tumor cell proliferation was
estimated by scoring Ki-67 positive cells from 0 (no positive cells)
to 3 (mostly positive). The frequency of CXCR4+MET+CD44+
cells was not significantly associated with Ki-67 scores (Supple-
mentary Fig. 1i).
We also established PDX through subcutaneous transplanta-
tion of tumor cells into immune-compromised mice. PDX grow
from about 15% of ccRCCs, but take rates were higher from
primary tumors of patients with metastases13. This prompted us
to establish xenografts from primary tumor tissue if distant
metastases were present (Fig. 2a). With this procedure we
established four PDX from eight patients. Cells from three
subcutaneous tumors were triple-sorted (Supplementary Fig. 2a)
and re-transplanted orthotopically into the renal parenchyma to
test their tumor-initiating potential. Low numbers of CXCR4+
MET+CD44+ cells initiated tumor growth, while negative
samples, with one exception, failed to do so (Fig. 2b). To
examine whether CXCR4+MET+CD44+ cells produced hetero-
geneous tumors, we compared the orthotopic xenografts with the
parental subcutaneous tumors. The histological diversity of the
parental xenografts was re-established in the orthotopic xeno-
grafts (Fig. 2c). Immunofluorescence showed that PDXs were
positive for both CA9 and CD10 (Supplementary Fig. 2b),
confirming their ccRCC identity. Ki-67 scores in subcutaneous or
orthotopic PDX were similar to or higher than in corresponding
primary tumors (Supplementary Fig. 2c).
Immunofluorescence for CXCR4, MET, and CD44 confirmed
that CXCR4+MET+CD44+ cells are rare in ccRCC tumors and
subcutaneous PDX (Fig. 2d). Their low levels in orthotopic tumors
indicated that transplanted CXCR4+MET+CD44+ cells differ-
entiated and lost marker expression during tumor formation. We
observed no preferential location of CXCR4+MET+CD44+ cells
within the tumors, even though there were marked intra- and
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Fig. 1 Analysis of ccRCC cancer stem cells. a Representative FACS of single-cell suspensions of ccRCC cells using the markers CXCR4, MET, and CD44.
Axis label of sidescatter is a multiple of 1000. b Limiting dilution assay of the sphere formation capacity of CXCR4+MET+CD44+ and CXCR4−MET−
CD44− cells (n= 4, single-cell suspensions of independent patients): 1–250 cells per well were seeded and cultured for 7 days, and all wells with >1 sphere
were counted as positive. 10 wells per concentration were analyzed. c Representative image of spheres of the two phenotypes after 7 days of culture (Scale
bar, 25 µm) (n= 4, single-cell suspensions of independent patients). d Quantification of sphere size of CXCR4+MET+CD44+ and CXCR4−MET−CD44−
cells after 7 days of culture (n= 125 CXCR4+MET+CD44+ spheres and 83 CXCR4−MET−CD44− spheres). Shown is the diameter in µm/100, line
represents median size and error bars show the interquartile range. p-value was calculated by two-sided Mann–Whitney test. Frequencies of CXCR4+
MET+CD44+ cells in ccRCCs from patients with (e) pathological stage (pT) 1/2 (n= 22) or 3/4 (n= 19), (f) Fuhrman grade (G) 1/2 (n= 34) or 3/4 (n=
7), (g) without (n= 31) or with (n= 10) venous invasion (V), (h) without (n= 34) and with (n = 7) lymph node invasion (L), and (i) without (n= 33) or
with (n = 8) distant metastases (M) at the time of surgery. Numbers represent single-cell suspensions of individual patients. Boxes show the 25, 50, and
75 percentiles, whiskers the 10 and 90 percentiles. Outliers are shown as dots. p-values were calculated by two-sided Mann–Whitney test.
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inter-patient differences in the expression of single markers. Few
CD44−positive cells were detected in areas with a predominance
of nested clear cells but were mostly present in dedifferentiated
areas of the tumor (Supplementary Fig. 2d). MET was often
strongly positive at tumor edges and more diffusely detected in the
centers (Supplementary Fig. 2e). CXCR4 expression was detected
in single cells, rather than clusters of cells, throughout the tumor
(Fig. 2d).
VCAM1, which has been proposed to mark the cell-of-origin
in ccRCC31, generally overlapped with MET in primary tumors
and xenografts (Fig. 2e). CXCR4+MET+CD44+ were mostly
positive for VCAM1, suggesting that the latter might represent a
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subpopulation of VCAM1+ cells in ccRCC. We further marked
proximal tubules with lotus tetragonolobus lectin (LTL) and
stained for the distal-tubule marker Calbindin. We detected LTL-
positive cells in all tumors, albeit with varying frequency, but were
unable to detect any Calbindin-positive tumor cells (Supplemen-
tary Fig. 2f, g). The specificity of both markers was confirmed in
normal-adjacent tissue (Supplementary Fig. 2h, i). This confirms
RNA sequencing data suggesting that ccRCC maintains the
expression features of proximal tubule cells31,32. Together, these
data show that high numbers of self-renewing CSCs correlate
with the features of high tumor progression and metastasis.
Characterization of ccRCC spheres and organoids. We cultured
CXCR4+MET+CD44+ cells as spheres under non-adherent con-
ditions and as organoids in Matrigel (see scheme in Fig. 3a). Sphere
and organoid culture conditions were similar to those previously
described11,33,34 but were adapted to the specific growth factor
needs of kidney cancer cells. CXCR4+MET+CD44+ cells became
enriched in sphere cultures (Fig. 3b and Supplementary Fig. 3a)
and could be passaged without significant loss of spheres (Sup-
plementary Fig. 3c). This demonstrates that sphere cultures enrich
and maintain self-renewing CSCs. CXCR4+MET+CD44+ cells
were also required for the initial formation of cultured organoids
(Supplementary Fig. 3d), but their frequency quickly decreased,
becoming comparable to those found in the primary tumors. This
indicates that cells undergo differentiation in organoids (Fig. 3c
and Supplementary Fig. 3b).
In sphere cultures, cells aggregated into solid structures
(Fig. 3d), which contrasted with organoid cultures, where the
majority of cells formed large hollow cysts (Fig. 3e). A subset of
organoids exhibited other morphologies, such as more solid
structures or intertwined tubes (Supplementary Fig. 3e). Such
differences were observed within organoids of the same patient, as
well as from different individuals. Immunofluorescence staining
of spheres revealed weak E-cadherin (ECAD) with no preferential
association to the cell surface (Fig. 3f, upper left). In contrast, in
organoids E-cadherin located to lateral cell membranes (Fig. 3g,
upper left) indicating epithelial cell differentiation. Carbonic
anhydrase IX (CA9) staining confirmed that both types of
cultures consisted of kidney cancer cells (Fig. 3f, g, upper right)35.
LTL, which can be used to mark proximal tubule brush borders,
only marked organoid cells (Fig. 3f, g, middle left). Although LTL
staining was generally diffuse, it was localized apically in some of
the organoids, which is typical for proximal tubules (Supplemen-
tary Fig. 3f). Most sphere cells were positive for CXCR4, MET,
and CD44, but only a subset of cells of the organoids was positive
for all three markers, further indicating differentiation of
organoid cells (Fig. 3f, g, middle right and Supplementary
Fig. 3h). VCAM1-positive cells were detected in spheres and
organoids (Fig. 3f, g, lower left), and both sphere and organoid
cultures contained Ki-67-positive cells (Fig. 3f, g, lower right).
Electron microscopy revealed that organoids contained an
inner lumen (marked with L), and consisted of layers of tightly
packed cells with apical brush borders (Fig. 3h), which confirms
epithelial differentiation. Lateral contacts between cells consisted
of tight junctions (red arrowheads), adherens junctions (AJ)
and desmosomes (D) (Fig. 3h). Cells on the basal side exhibited
smooth basement membranes (Fig. 3h). Organoid cells contained
glycogen deposits (asterisks) and lipid droplets (arrows), both
typical characteristics of ccRCC36,37. The presence of glycogen
was further confirmed by Periodic acid Schiff (PAS) staining
(Supplementary Fig. 3g). In summary: markers, structures and
junctions confirm that sphere cultures enrich for undifferentiated,
self-renewing cells, while organoids show clear epithelial and
kidney-specific cell differentiation.
WNT and NOTCH are activated in kidney CSCs. We carried
out genome-wide expression profiling of FAC-sorted CXCR4+
MET+CD44+ cells, sphere cells and non-sorted control cells from
the tumors of three patients. A heatmap clearly distinguished
sphere and CXCR4+MET+CD44+ cells from controls (Fig. 4a).
Gene ontology (GO) analysis of the gene signature common to
spheres and CXCR4+MET+CD44+ cells (all genes with FC > 1.5
or <–1.5 and p-value < 0.05 were considered) in either spheres
and CXCR4+MET+CD44+ cells revealed an activation of genes
associated with cell fate determination (i.e. KLF4, SOX9), kidney
development (PAX2, SALL1), stem cell maintenance (PROM1,
ALDH1A1) and chromatin modifications (MYST3) (Fig. 4b, left
part and Supplementary Fig. 4a; see also Supplementary Data 1
for the full gene list). A Kegg pathway analysis38 revealed further
that the CSCs exhibited activation of WNT and NOTCH sig-
naling, as seen by the top-scoring genes TCF7L2, TCF3, LGR4,
AXIN2, and EP300 (WNT targets) and RBPJ, NOTCH3, HES1,
and JAG1 (NOTCH targets) (Fig. 4b). Expression of these genes
was validated in CXCR4+MET+CD44+ cells and sphere cultures
derived from 10 further ccRCC tissues (Supplementary Fig. 4b, c).
Luciferase reporter gene assays confirmed a significant activation
of WNT and NOTCH components in spheres and CXCR4+MET
+CD44+ cells, in contrast to adherent cells, which are not self-
renewing33,34 (Fig. 4c, d). Moreover, WNT and NOTCH target
gene expression was lower in organoids (Supplementary Fig. 4d,
e), again indicating that differentiated cells accumulate in orga-
noids. A knockdown of CTNNB1 (β-catenin) and NOTCH1 by
siRNA treatment strongly reduced the numbers of spheres in the
cultures (Fig. 4e, f). We also examined the secretion of two WNT
ligands, which showed high expression in the microarray in
sphere and organoid culture supernatants using ELISA. The
secretion of WNT10A but not WNT7B was elevated in sphere
cultures when compared to the secretion in adherent or organoid
cultures from the same patients (Fig. 4g, h).
In sphere cultures, we further observed that ectopic activation
of WNT signaling using a β-catenin-LEF1 fusion protein39
(Fig. 4i) triggered a strong induction of NOTCH signaling
(Fig. 4j). In contrast, MAML, NICD, or NOTCH1 siRNA
transfections had no significant effects on WNT signaling
(Supplementary Fig. 4f–h). The WNT activation of NOTCH
signaling was accompanied by transcriptional upregulation of
JAG1 and HES1 (Fig. 4k). A lower WNT-dependent activation of
NOTCH was observed in organoid cultures (Supplementary
Fig. 4i–k). These data indicate that NOTCH is upregulated by
Fig. 2 Xenotransplantation and in vivo localization of CXCR4+MET+CD44+. a Representative images of xenotransplanted mice, and subcutaneous and
orthotopic tumors (Scale bars, 0.5 cm). b Tumor formation by CXCR4+MET+CD44+ and CXCR4−MET−CD44− cells: cells were isolated from
subcutaneous tumors, FAC-sorted and orthotopically transplanted into the renal parenchyma at the indicated cell numbers. Tumor formation was analyzed
when mice showed symptoms or tumors were palpable. c Representative HE of primary ccRCC specimens and corresponding subcutaneous and orthotopic
xenografts (scale bars, 50 µm). d Representative immunofluorescence of CXCR4, MET, and CD44. CXCR4+MET+CD44+ cells are highlighted in dotted
lines and arrows. Immunofluorescence of each individual marker is shown for clarity (sale bars, 50 µm). e Representative immunofluorescence of VCAM1.
Location of CXCR4+MET+CD44+ cells are highlighted in dotted lines (scale bars, 50 µm). Stainings were performed in three independent PDX and in 42
ccRCC specimens.
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WNT signaling in renal cancer stem cells, mediated by the
transcriptional upregulation of JAG1, a mechanism previously
described in the intestine40.
To confirm that the stem cell signature was associated with the
clinical course of ccRCC, we examined gene expression data that
had previously been obtained from 28 additional ccRCC patients
(Supplementary Table 2)41. In these analyses, we included all
genes with a FC > 1.5 or <−1.5 and p-value < 0.05. Supervised
hierarchical clustering showed that tumors could be distinguished
from normal tissues from the same patients (Supplementary
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Fig. 4l, top part, compare orange with blue). The heatmap
revealed that the stem cell gene signature was differentially
expressed in normal kidney tissues and tumors (Supplementary
Fig. 4l). We selected all genes associated with kidney develop-
ment, stem cell maintenance, WNT, and NOTCH signaling (all
genes plotted in Fig. 4b) and compared the expression of these
genes with patient survival. Kaplan–Meier survival analyses
showed that the stem cell signature was associated with poor
overall survival of patients (Supplementary Fig. 4m). Poor
survival was also associated with the expression of individual
WNT (DKK3) or NOTCH signaling (NOTCH3) genes (Supple-
mentary Fig. 4n). We confirmed these data from our small patient
cohort using RNA sequencing data from the TCGA KIRC study3.
The stem cell signature (Fig. 4l), the combination of all
deregulated WNT and NOTCH pathway genes (Fig. 4m), or
DKK3 (Fig. 4n) and NOTCH3 (Fig. 4o) expression alone were
associated with the overall survival of the 462 patients.
We next used the CEL-Seq technique42,43 to carry out single-
cell sequencing of CXCR4+MET+CD44+ cells. The aim was to
explore the extent of heterogeneity in ccRCC stem cell
populations and to determine the fraction of the cells which
exhibited WNT and NOTCH activation. We analyzed 90 cells per
sample and combined both datasets to identify only those genes
whose expression commonly varied in both datasets (6775 genes)
(Supplementary Fig. 5a, b). Cluster analysis was performed and
most significant canonical clusters were aligned and subjected to
tSNE analysis44. This revealed three clusters (Fig. 5a, marked by
different colors), which were not unique to individual patients, as
cells from each sample were found in each of the clusters. We
identified the top 20 genes of each cluster (Fig. 5b, indicated on
the right). The genes included extracellular and transmembrane
genes and extracellular vesicles, such as CXCL1, CXCL6, MMP7,
CD70, and COL5A1. While the cancer stem cell genes and WNT
and NOTCH signaling genes were not included in this list, we
found that clusters 1 and 3 showed higher expression of WNT
and NOTCH pathway genes, stem cell genes and kidney-specific
genes, for instance LGR4, TCF7L2, JAG1, ALDH1A1, and PAX2
(Fig. 5c). Other stem cell-specific genes were expressed across all
three clusters (Supplementary Fig. 5c). These results indicate that
while cluster 1 and 3 have the highest expression of certain CSC
genes, in general all clusters share expression of a subset of CSC
genes. Interestingly, WNT and NOTCH genes are both activated
in the same cell clusters and do not mark different subpopula-
tions of cells.
Collectively, we conclude that spheres and CXCR4+MET+
CD44+ cells share a gene signature that distinguishes them from
controls and characterizes stem cells in renal carcinoma. When
we compared this with patient data, we observed that the
activation of the stem cell signature as well as individual genes
involved in WNT and NOTCH signaling were associated with
worse survival. The connection between WNT/NOTCH signaling
and the phenotype suggested that these pathways could represent
a weakness that might be exploited in targeting CSCs and PDXs.
Inhibitors of WNT and NOTCH reduce CSC and organoid
growth. We examined the effects of inhibitors of WNT and
NOTCH signaling in all our experimental models: sphere and
organoid cultures and PDXs. First, sphere cultures were treated
with the WNT inhibitor ICG-00145 or the NOTCH inhibitor
DAPT46. We analyzed sphere cultures of a subset of 41 patients
from the total of 55 (Supplementary Table 1). Cultures from a
majority of patients responded to ICG-001, while DAPT inhibited
cultures from three other patients, both in concentration-
dependent manners and within one week (Fig. 6a, b). A few
cultures failed to respond (Supplementary Fig. 6a, d). Sphere
cultures with ICG-001 IC50 < 20 µM or DAPT IC50 < 30 µM
were considered as responders. The responses could be classified
into four subgroups: ICG-001 responders (71%), DAPT respon-
ders (63%), ICG-001/DAPT double responders (46%) or non-
responders (12%) (Fig. 6c, Supplementary Table 3). Responses to
either ICG-001 or DAPT did not correlate with the pathological
stage or grade of the cancer or percentage of CXCR4+MET+
CD44+ cells (Supplementary Table 4) indicating that specific
mechanisms of response exist. We also applied combinations of
the two inhibitors at low concentrations for which single inhi-
bitors produced only minimal effects (Fig. 6d). Combinations had
a strong effect on ICG-001/DAPT double responders, but were
less effective in non-responders indicating that double responders
might also benefit from the combined treatment with both
inhibitors (Fig. 6d). ICG-001 suppressed WNT target genes and
DAPT suppressed NOTCH target genes in responding sphere
cultures (Fig. 6e, f), but not in non-responders (Supplementary
Fig. 6b, d). We also examined sphere cultures using other inhi-
bitors directed against the receptors used above for sorting CSC,
but these were less effective than WNT and NOTCH inhibition:
the MET inhibitor Crizotinib47 inhibited sphere growth in 44% of
specimens, and the CXCR4 chemokine receptor inhibitor
AMD310048 in 17%.
We further analyzed the effects of inhibiting the two pathways
in ccRCC organoid cultures: WNT inhibitors had potent effects
on the organoids, but the response to NOTCH inhibitors was
weak (Fig. 6g, h). Moreover, ICG-001 suppressed WNT target
genes in organoids, while DAPT had little or no effect (Fig. 6i, j).
We reasoned that WNT inhibition had a strong effect on both
self-renewal and differentiation, which is supported by the fact
that ICG-001 inhibited growth in both spheres and organoids.
NOTCH inhibition, in contrast, could have one of two effects:
either it targeted more specifically self-renewing cells and had a
weaker effect on their differentiation during organoid forma-
tion, or it had more moderate effects on these cells, permitting
their differentiation before they were targeted by the treatment.
We therefore reseeded DAPT-treated organoids and observed
an impaired secondary growth of organoids (Supplementary
Fig. 6e). We conclude that in the initial passage, DAPT
treatment may have reduced the CSC pool preventing cells to
regrow in the second passage. To exclude non-specific toxicity,
we treated spheres and organoids derived from normal-adjacent
tissue. DAPT had no significant effect on the five sphere and
organoid cultures that were examined (Supplementary Fig. 6f).
ICG-001 also produced no significant toxicity in sphere cultures,
but led to a reduction of organoid growth (Supplementary
Fig. 6g).
Fig. 3 Characterization of ccRCC-derived sphere and organoid cultures. a Human ccRCCs were collected at nephrectomy. Single cells were isolated and
seeded as spheres in non-adherent conditions or as organoids in Matrigel. b, c Percent of CXCR4+MET+CD44+ cells obtained by FACS after 7 days of
sphere or organoid cultures. Axis label of sidescatter is a multiple of 1000. d, e Brightfield images and HE staining after 7 days of sphere and organoid
culture (scale bars, 100 µm). f, g Immunofluorescence for Carbonic anhydrase IX (CA9), E-Cadherin (ECAD), LTL, CXCR4, MET, CD44, VCAM1, and Ki-67
(scale bars, 25 µM). Stainings were performed in five sphere and organoid cultures of five independent patients. h Transmission electron microscopy of
representative organoid cultures (see scale bars for sizes): L, luminal side; D, desmosomes; AJ, adherens junctions; arrowheads, tight junctions; arrows,
lipid droplets; asterisks, glycogen deposits. TEM was performed on organoid cultures of three selected patients.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14700-7 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:929 | https://doi.org/10.1038/s41467-020-14700-7 | www.nature.com/naturecommunications 7
To exclude that the effects of ICG-001 were due to unspecific
events, we tested additional WNT inhibitors in specimens that
responded to ICG-001: the TANKYRASE inhibitor XAV93949,
the β-CATENIN inhibitor LF350, and the Porcupine inhibitor
C5951. While each of the WNT inhibitors reduced sphere
formation and organoid growth, they showed different
efficiencies, decreased the expression of WNT target genes to
varying levels, and some had stronger effects on normal cells.
This indicates that ICG-001 is the most suitable inhibitor for
further experiments (Supplementary Fig. 6h–j). The MAML
inhibitor IMR-1 showed strong effects both on spheres and
organoids. In general, inhibition by IMR-1 was stronger than
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the effects observed by DAPT, specifically in organoids, yet it
also had pronounced effects on normal cells (Supplementary
Fig. 6k).
Inhibitors of WNT and NOTCH signaling reduce PDX growth.
We also examined the effects of WNT and NOTCH inhibition
in our third model, PDXs. PDX (PDX1 and PDX4) were re-
passaged, and once tumors became palpable, animals were
allocated to different systemic treatments. PDX4 mice showed
a marked reduction of tumor volumes when treated with
ICG-001 (Fig. 7a and Supplementary Fig. 7a); at 26 days,
their tumors were 44% smaller than those of control animals.
The NOTCH inhibitor DAPT had no significant impact on
the tumor volumes (Fig. 7a). We examined the tumors histo-
logically following treatment: we found that large areas of the
tissue became fibrotic upon ICG-001 treatment (Fig. 7c, middle
row). At the cellular level, these tumors contained fewer pro-
liferating cells, as determined by staining with Ki-67 (Fig. 7c,
middle row).
Next, PDX1 animals were subjected to single ICG-001 and
DAPT and combined therapies. Treatment with ICG-001 led to
strong reductions of tumor volumes; DAPT had less pronounced
effects (Fig. 7b and Supplementary Fig. 7b). At day 93, ICG-001
and combined treatments reduced tumor volumes by 90%,
while DAPT reduced them by 52% (Fig. 7b and Supplementary
Fig. 7b). Histological examinations revealed that ICG-001-
and DAPT-treated tumors contained necrotic regions and a
Fig. 4 Activation of WNT in NOTCH signaling in CXCR4+MET+CD44+ and spheres.Microarray analysis of spheres, FAC-sorted CXCR4+MET+CD44+
and control cells from three ccRCCs. a Heatmap and hierarchical clustering of the 500 most variable probes. b log2 fold changes of top-scoring genes
associated with the GO terms kidney development, stem cell maintenance, WNT and NOTCH signaling. Data are shown as mean, error bars represent s.d.
(n= 3 patients). c, d WNT or NOTCH luciferase reporter gene assays of sphere and adherent cultures of ccRCC (n= 5 independent patients). Data are
shown as mean, error bars represent s.d., p-values calculated by two-sided t-test. e, f siRNA knockdown of CTNNB1 or NOTCH1 in spheres (n= 5 patients).
Data are shown as mean, error bars represent s.d., p-values calculated by two-sided t-test. g, h ELISA for WNT10A and WNT7B secretion of adherent,
organoid and sphere cultures (n= 6 patients). Supernatants were collected after 7 days of culture. Values were normalized to the number of cells per ml
medium and are represented as ng protein per 106 cells. Line represents mean protein concentration and error bars show the s.d. p-values: *<0.05,
***<0.001 by RM ANOVA with Dunnett’s post-test (two-sided). i, jWNT or NOTCH luciferase reporter gene assays of sphere cultures (n= 5 independent
patients) transfected with a β-Catenin-LEF1 fusion protein encoding plasmid. Data are shown as mean, error bars represent s.d., p-values calculated by two-
sided t-test. k Expression of WNT and NOTCH pathway genes measured by RT-qPCR in β-Catenin-LEF1-transfected spheres (n= 5 patients). Data are
shown as mean, error bars represent s.d., p-values: **<0.01, ***<0.001, ****<0.0001 by two-sided, paired t-test. Overall survival of TCGA KIRC specimens
with or without the stem cell signature (l), the WNT and NOTCH signature (m), or high (>median) or low (<median) DKK3 (n) or NOTCH3 expression
(o). Stem cell signature predictor score was calculated by multivariate Cox regression, patients were stratified into groups according to the median
predictor score. Censored patients are presented as vertical lines. Significance was tested by log rank test (two-sided).
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Fig. 5 Single-cell sequencing of CXCR4+MET+CD44+ cells. Single-cell RNA-Seq was performed on 90 cells per patient by using the CEL-Seq2 method.
Canonical cluster analysis was performed on common variable genes in the combined datasets, and tSNE clusters were subsequently identified. a tSNE plot
of single cells, clusters marked in different colors, b Heatmap of the top 20 markers for each cluster. c Expression of WNT, NOTCH and stem cell marker
genes in each cluster. Data are shown as scatter plot, violin plot represents data density.
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remarkable reduction in numbers of proliferating cells (Fig. 7d,
middle and lower rows).
Immunostaining for β-CATENIN and in situ hybridization
for AXIN2 in PDX4 showed that after ICG-001 treatment,
tumor tissues displayed a reduced expression of these markers,
in contrast to vehicle-treated controls (Fig. 7e). In contrast,
DAPT treatments did not markedly alter NOTCH1 and JAG1
expression; in fact, the nuclear localization of NOTCH1 was
even more pronounced (Fig. 7g). Similar staining procedures in
PDX1 confirmed a reduction of all four markers under
treatment with either ICG-001 or DAPT, corresponding to the
effects on tumor volumes (Fig. 7f, h). FACS experiments in
PDX4 confirmed that effective WNT inhibition was accom-
panied by reduced numbers of CXCR4+MET+CD44+ cells,
while DAPT treatment resulted in higher numbers of these cells
(Supplementary Fig. 7c). A comparative expression analysis of
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Fig. 6 Pharmacological inhibition of WNT and NOTCH signaling in ccRCC spheres and organoids. a, b ccRCC sphere cultures were treated with 5–50 µM
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WNT and NOTCH genes showed a markedly lower expression
of JAG1 in PDX4, which potentially explains the lower response
to DAPT inhibition (Supplementary Fig. 7d). The responses of
the two types of xenografts were similar to those of sphere
cultures from corresponding patients (Supplementary Fig. 7e),
confirming that sphere cultures are useful surrogates for tumor
responses.
PDX1 tumors were also subjected to treatment with the
clinically approved substances sunitinib, sorafenib, bevacizumab,
and everolimus. Responses were assessed according to the
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RECIST criteria52 as progressive diseases (personal communica-
tion with EPO). We did not observe any signs of unspecific
toxicity in mice at the end of the treatment period, as assessed by
weight loss, general appearance, and macroscopic examination of
visceral organs. Both inhibitors have also been used in other
preclinical models in the same or lower concentrations53,54. In
conclusion, xenograft treatments provide further evidence that
specific patient groups could profit from therapeutic WNT and
NOTCH inhibition.
Discussion
CSCs play a central role in tumors’ resistance to therapies and
their metastatic potential, and treatments are unlikely to become
cures unless they target this subpopulation. Work on human
ccRCC, however, had not led to a clear characterization of
CSCs8,9,22,55 or to concepts to targeting them therapeutically. We
identified a subpopulation of self-renewing CSCs that could be
identified by a CXCR4+MET+CD44+ profile. Analyses of gene
and protein expression revealed an activation of WNT and
NOTCH signaling in these CSCs. Inhibition of WNT and
NOTCH signaling through small molecular weight compounds
blocked CSCs.
Current treatments for human ccRCC include various combi-
nations of antiangiogenic drugs, mTOR inhibitors, and immu-
notherapy drugs that extend the lives of many patients5.
However, these treatments rarely lead to complete remission, and
nearly all of the tumors progress within 2 years7. Our work
indicates that WNT and NOTCH signaling exert essential func-
tions in CSCs and thus represent a weakness that could be
therapeutically exploited.
We developed treatment regimens based on small molecule
inhibitors that target components of WNT and NOTCH sig-
naling. We applied the inhibitors to three model systems
developed from tumors of ccRCC patients. CSCs produced non-
adherent, self-renewing sphere cultures, and organoids, which
differentiate to recapitulate the heterogeneous cell types
observed in patients’ primary tumors. The third method was to
develop PDX animals by transplanting aggressive ccRCCs into
immune-compromised mice.
Two other methods to culture ccRCC organoids have recently
been described56,57. The first yielded organoids with a limited
expansion capacity and a low rate of success. Those organoids
showed less epithelial polarization than the organoids we pro-
duced here. Interestingly both previous methods described a
maintenance of genomic clones in the organoids, supporting the
assumption that organoids are representative of the primary
tumors. Future work will be needed to clarify the differences
between the cultivation methods and their significance.
Each of our models diverges from human disease in ways that
could not be predicted without direct comparisons to each other
and findings from patients. A crucial factor in the development of
personalized approaches to the treatment of ccRCC will be the
speed at which models can be developed from individual patients’
diseases. The sphere and organoid cultures require one week for
isolation and expansion and one week for attempts at treatment.
We regard this as an important step toward the translation of
these methods into early phase clinical trials.
We could distinguish four classes of sphere cultures based on
the type of inhibition to which they responded: WNT responders
(71%), NOTCH responders (63%), WNT/NOTCH double
responders (46%) or non-responders (12%). Organoids were
highly sensitive to treatment with WNT inhibitors, while treat-
ment with the NOTCH inhibitor DAPT had a markedly weaker
effect. This may mean that WNT is required for both self-renewal
and differentiation, while NOTCH is mainly involved in self-
renewal. This notion is supported by our observation that pre-
DAPT-treated organoids cannot be re-seeded, arguing that they
undergo a depletion of the stem cell pool. Kidney PDX models are
difficult to generate, but the tumors we could examine responded
to both WNT and NOTCH inhibition in a manner comparable to
the responses of sphere cultures.
Beyond the WNT and NOTCH responders, we identified
smaller subgroups of CSCs that were inhibited by targeting other
CSC-relevant molecules: CXCR4 with AMD3100 and MET with
Crizotinib. While the results suggest that targeting surface mar-
kers of CSCs is less effective than targeting their downstream
pathways, it also suggests that specific subgroups of patients
might benefit from these strategies. Our work thus suggests that
defining the features of patients’ CSCs may make it possible to
rapidly stratify their tumors as a route to better treatments5. It
should also help distinguish patients likely to benefit from ther-
apy from those who should be spared58–60. The mechanisms by
which these tumors develop resistance to therapies will need to be
further explored.
We found higher numbers of CSCs in cases of ccRCC char-
acterized by high pathological stages and metastases. Their pre-
sence is predictive providing the CSCs have been accurately
defined. CD105 and CXCR4 alone, used in previous studies to
identify CSCs in kidney cancers8,9, were less predictive of tumor
progression. Kaplan–Meier survival analyses revealed an asso-
ciation between our new stem cell signature and patients’ survival.
This confirms a trend observed in other tumors, such as breast
cancer, where stem cell signatures correlated with tumor
aggressivness61.
A major limitation of this study is the low number of xeno-
grafts used to test tumor-initiating capacity. In our hands,
xenografts of RCC grew slowly with 3-month latency until the
formation of subcutaneous tumors, which limited expansion of
these tumors. After sorting for CSCs, cell numbers were limited
and did not allow for three technical replicates per concentration.
We also used single-cell sequencing to determine the degree of
heterogeneity within the CSC population. This yielded three
subpopulations, two of which exhibited high expression of mar-
kers known to be associated with stem cells and kidney devel-
opment. These two populations also showed a high expression of
WNT and NOTCH signaling components and high expression
from the corresponding target genes.
Our data help establishing a crucial connection between WNT
and NOTCH signaling and the biology of CSCs in ccRCC. In
contrast to VHL, WNT, and NOTCH mutations are rare in
ccRCC2,3. We propose that cancer stem cells use autocrine
Fig. 7 Inhibition of WNT and NOTCH signaling in patient-derived ccRCC xenografts. a, b Treatment schemes and quantifications of tumor volumes of
PDX4 and PDX1 tumors (n= 3 tumors in each group) treated with 100mg/kg ICG-001 (green diamond), 10 mg/kg DAPT (blue squares), combination
(black diamond, PDX1 only) or vehicle (red circles) every three days. Data are shown as mean, error bars represent s.d., p-values: *<0.05, *<0.01,
***<0.001 by two-way ANOVA with Tukey post-test (two-sided). c, d HE and Ki-67 staining of representative sections of tumors of PDX1 and PDX4 (scale
bars, 50 µm). e, f Immunofluorescence of β-CATENIN (scale bars, 50 µm) and in situ hybridization for AXIN2 (scale bars 100 µm) in PDX4 and PDX1
tumors in mice treated with 100mg/kg ICG-001. g, h Immunofluorescence of NOTCH1 and JAG1 in PDX4 and PDX1 tumors in mice treated with 10 mg/kg
DAPT (scale bars, 50 µm).
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mechanisms to upregulate WNT signaling, as shown by the
higher secretion of WNT10A and by the fact that NOTCH sig-
naling is activated downstream of WNT. WNT10A has previously
been suggested as an oncogenic WNT ligand in ccRCC62, but it
had not been linked with CSCs. Several other mechanisms
involving WNT and NOTCH upregulation have been described
in kidney cancer. VHL and other crucial drivers of kidney cancer
activate both the WNT and NOTCH pathways. For instance, the
loss of VHL stabilizes β-CATENIN via JADE163. Activated β-
CATENIN has been associated with advanced kidney cancers and
lower patient survival64. WNT signaling can also be promoted by
hyper-activated MET observed in ccRCC65. NOTCH signaling is
activated through VHL/hypoxia signaling66 or independently of
VHL67. These findings are consistent with our results and the
effects of inhibiting these pathways in our model systems. We
interpret this to mean that they support new strategies to treat
ccRCC based on the disruption of crucial mechanisms in can-
cer stem cells that play an essential role in ccRCC.
Methods
Patient samples. ccRCC specimens were collected at the Department of Urology,
Charité-University Medicine, Berlin (characteristics in Supplementary Table 1).
The project was approved by the ethics committee of the Charite—University
Hospital (EA1/134/12) and informed consent was obtained from all patients.
Samples were processed within 24 h after surgery. The tissue was extensively
washed in PBS, minced into cubes smaller than 1 mm3, digested enzymatically
using collagenase P and filtered through sieves with 100 and 40 µm pore size.
Subsequently, erythrocytes were lysed and leukocytes were depleted by MACS
using anti-CD45 micro-beads (Milteniy BioTec). The selection of samples for
specific analysis was based on tissue availability.
Primary culture. Tumor cell suspensions at 100.000 cells/ml were seeded as non-
adherent sphere cultures in Poly-HEMA-pretreated (Sigma Aldrich) 24-well plates
(Fisher Scientific) in DMEM/F12, supplemented with 20 ng/ml EGF, 20 ng/µl
FGFb, 4 µg/µl Heparin, 1× B27 (Fisher Scientific), 1× Penicillin/Streptomycin
(Gibco), and 125 µg/ml Amphotericin B (PAA). Cells were cultured for 7 days
before harvesting or re-passaging.
For organoid cultivation, fresh tumor cell suspensions were prepared as
described above and seeded at 15.000 cells per well in 25 µl growth factor-reduced
Matrigel (Corning) drops (75% Matrigel, 25% growth medium) in 48-well plates.
After polymerization, Matrigel lenses were overlaid with 250 µl DMEM/
F12 supplemented with 20 ng/ml EGF, 20 ng/µl FGF, 4 µg/µl Heparin, 1× B27
(Fisher Scientific), 1× Penicillin/Streptomycin (Gibco), and 1.25 µg/ml
Amphotericin B (PAA). Medium was changed every other day. Passaging of
organoids was performed every 7 days: Matrigel was broken up by pipetting up and
down several times, and organoids were collected in a tube. After centrifugation at
300g for 5 min, organoids were dissociated in TrypLE (Fisher Scientific) for 10 min.
Cell cluster were reseeded as described above and a typical split ratio of 1:3.
Organoids were filtered using a 40 µm mesh in the first passage to clear the culture
from remaining single cells. Several downstream experiments demanded seeding of
single-cell suspension. In this case, organoids were dissociated in TrypLE for
30 min. Early passage organoids were frozen in Recovery Cell Culture Freezing
Medium (Thermo Fisher) according to the manufacturer’s recommendations. A
detailed protocol will be provided by the authors upon request.
Adherent cultures were grown in MEM in standard tissue culture plates (Fisher
Scientific) with Earle’s salts supplemented with 10% FCS, 1× NEAA, 2 mM L-
Glutamin, 1× Penicillin/Streptomycin and 1.25 µg/ml Amphotericin B. Medium
was changed every 3 days and cultures were passaged at 80–90% confluency.
Fluorescence-activated cell sorting. Isolated tumors cells were analyzed with
FACS Aria I or Aria F Cell Sorters (BD Biosciences, Germany). Single staining was
performed for each marker for correct instrument setup. Stem cells were sorted by
anti-CD44-FITC (BD Biosciences), anti-CXCR4 (R&D Systems), biotin-anti-
mouse (Sigma), Streptavidin-APC (Life Technologies), and anti-MET antibodies
(Santa Cruz), anti-rabbit-Pacific Blue. Viable cells were identified by 7AAD
staining (BD Biosciences). Single cells were gated by plotting SSC versus FSC and
confirmed by gating FSC-A vs FSC-H and SSC-A vs. SSC-H. Viable cells were
identified by negative 7AAD staining. Gating strategy is shown for one patient in
Supplementary Fig. 8. Sorting efficiency was confirmed by resorting a subset of
sorted cells and was >95% for all experiments. For the remaining markers single
stainings were performed (see Supplementary Table 6 for a full antibody list).
Gene expression analysis. RNA was isolated from uncultured and unsorted
control cells, CXCR4+MET+CD44+ or sphere-cultured cells using the RNeasy
Mini Kit (Qiagen) and hybridized to the HumanHT-12 v4 bead chip (Illumina
Inc.) according to the manufacturers protocol. HumanHT-12 v4 bead chip data
were normalized and log-transformed in Partek Genomics Suite (Partek) and
analyzed using the limma package68 in R. We identified a stem cell signature that
included all genes that were upregulated in either spheres and CXCR4+MET+
CD44+ with FC > 1.5 or <−1.5 and p-value < 0.05. GO term enrichment and Kegg
pathway analyses were performed with DAVID38. The gene expression analyses of
28 fresh frozen ccRCC specimens has been performed previously at the Charité-
University hospital and only the data were used for this study (GEO Accession
Code: GSE66270 and GSE66271, for patient information see Supplementary
Table 2)41. Expression of stem cell genes was analyzed using the GeneSpring GX
software (Agilent), and supervised hierarchical clustering was performed in
Genesis69.
Single-cell sequencing. Single-cell analysis was performed using the CEL-Seq2
method published previously42. Single CXCR4+MET+CD44+ cells were sorted
into 96-well plates containing all reagents for reverse transcription. Primers with
unique cell barcodes for reverse transcription can be found in the publications42,43.
SuperScript II (Thermo Fisher) was used for reverse transcription. AmPure XP
beads (Beckman Coulter) was used for RNA clean-up. Single-cell RNA amplifi-
cation was performed by in vitro transcription using the MEGAscript T7 tran-
scription kit (Thermo Fisher). Amplified products were further proceeded to
library preparation using Illumina sequencing primers. Paired-end sequencing was
performed on a HiSeq 2500 sequencing system in a manner of 16 bases for read 1
(barcode read), 7 bases for the Illumina index and 51 bases for read 2.
Single sequencing raw BCL files were converted to FASTQ using the
BCL2FASTQ software (Illumina). FASTQ files were processed using a multistep
python library available on GitHub (https://github.com/yanailab/celseq2). Briefly,
data were de-multiplexed using the barcode from read 1, and UMIs were attached
to read 2 metadata. Using BowTie2, reads were mapped to the Hg19 reference
genome, and raw reads were counted using a modified HTSeq-count script. Data
were then analyzed using the Seurat package in R70 (http://satijalab.org/seurat/).
All cells expressing less than 200 genes and all genes expressed in less than three
cells were excluded from further analysis. The datasets of both samples were
combined for all downstream analysis. All data were scaled so that each gene had a
mean expression of 0 and a variation of 1 across all cells. Reads were log-
transformed and normalized to the total reads per sample to obtain RPM. To find
clusters across samples, we performed canonical correlation analysis and forwarded
these clusters to tSNE analysis. Cells whose variance could not be explained with
greater 2-fold variance in comparison to PCA were excluded from the tSNE plot.
Real-time quantitative polymerase chain reaction. Total RNA from sphere
cultures, organoids, and adherent cells was isolated using TRIZOL (Invitrogen),
and 1 µg total RNA was reverse transcribed using MMLV reverse transcriptase
according to the manufacturer’s instructions (Promega). RT-qPCR was performed
using the iCycler IQTM 5 multicolor real-time detection system (Bio-Rad), with
absolute SYBR green fluorescein (ABgene) using a standard protocol. Primer
sequences are listed in Supplementary Table 5. Primer specificity was tested by
melting curve analyses and gel electrophoreses. Expression values were normalized
to the endogenous control GAPDH and amplification efficiency using an adjusted
2−ΔΔCt method.
siRNA transfection and luciferase reporter gene assay. Adherent cultures were
transfected with 30 pmol siRNA oligos against CTNNB1, NOTCH1, or a control
oligo by using Lipofectamine 2000 according to the manufacturer’s instructions
(Invitrogen). Twenty four hours after transfection 100,000 cells/ml were seeded as
spheres in 24-well plates or reseeded in 6-well plates under adherent conditions.
Five days after transfection, spheres were counted under a microscope. Three
technical replicates per primary cell culture and group were analyzed. Knockdown
efficiency was analyzed by Western blotting and RT-qPCR.
Adherent cultures were transfected with 1 µg β-Catenin-LEF1 or empty plasmid
plus 1 µg TOPFlash, FOPFlash (Sigma Aldrich), or a RBPJ reporter plasmid and
20 ng pRL-TK plasmid (Promega) by using Lipofectamine 2000 according to the
manufacturer’s instructions (Invitrogen). Twenty four hours after transfection,
100,000 cells/ml were seeded as spheres in 24-well plates or reseeded in 6-well
plates under adherent conditions. Two days after transfection cells were lysed and
firefly and renilla luciferase activities were assayed according to the manufacturer’s
instructions (Promega). Three technical replicates per primary cell culture and
group were analyzed. Knockdown efficiency was analyzed by western blotting and
RT-qPCR.
Organoid cultures were transfected with 1 µg β-Catenin-LEF1, MAML1, NICD
or empty plasmid plus 1 µg TOPFlash, FOPFlash (Sigma Aldrich), or a RBPJ
reporter plasmid and 20 ng pRL-TK plasmid (Promega) by using Lipofectamine
2000. Briefly, organoids were dissociated with TrypLE. Single-cell suspensions were
mixed with transfection complexes in 48-well plates, spun down at 600g and
incubated at 37 °C for 4 h. Cells were seeded in Matrigel as described above and
48 h after transfection cells were lysed and firefly and renilla luciferase activities
were assayed according to the manufacturer’s instructions (Promega).
Adherent cultures were transfected with 2 µg TOPFlash, FOPFlash (Sigma
Aldrich), or a RBPJ reporter plasmid and 20 ng pRL-TK plasmid (Promega) by
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using Lipofectamine 2000 according to the manufacturer’s instructions
(Invitrogen). Twenty four hours after transfection, 100.000 cells/ml were seeded as
spheres in 24-well plates or reseeded in 6-well plates under adherent conditions.
Two days after transfection, cells were lysed and firefly and renilla luciferase
activities were assayed according to the manufacturer’s instructions (Promega).
Three technical replicates per primary cell culture and group were analyzed.
ELISA. Supernatants of sphere, organoid and adherent cultures were collected after
7 days of culture. Elisa for WNT7B and WNT10A (Dianova) was performed
according to the manufacturer’s instructions using 100 µl of undiluted supernatant.
Protein concentrations were calculated from WNT10A and WNT7B standard
curves and were normalized to the number of cells per ml medium. Values are
represented as ng protein per 106 cells. Two technical replicates were measured per
sample.
Inhibitor assays. Cells were seeded at 100.000 cells/ml in 24-well plates under
non-adherent conditions and treated with ICG-001, DAPT, XAV-939, C59, IMR-1,
and LF3 at the concentrations indicated in the Results for seven days. Medium was
changed after 3 days. Spheres > 25 µm were counted per well and sphere number
was normalized to number of spheres in untreated control.
Cells were seeded at 5.000 cells/ml in 9 µl Matrigel in 96-well plates and treated
with ICG-001, DAPT, XAV-939, C59, IMR-1, and LF3 at the concentrations
indicated in the results for seven days. Medium was changed every other day.
Metabolic activity was measured by Celltiter Glo assay (Promega) according to the
manufacturer’s instructions. Three technical replicates per concentration were
analyzed and values were normalized to non-treated controls.
Xenograft assay. All animal experiments were performed by EPO (Experimental
Pharmacology and Oncology, Berlin-Buch). Animal experiments were carried out
in accordance with the of the German Animal Protection Law and approved by the
local responsible authorities. EPO complies to the EU guideline “European con-
vention for the protection of vertebrate animals used for experimental and other
scientific purposes. (EST 123)”. Further, we handle our animals according to the
“Regulation on the protection of experimental scientific purposes or other Purposes
used animals”. Compliance with the above rules and regulations is monitored by
the Landesamt fuer Gesundheit und Soziales (LAGeSo) which is the responsible
regulatory authority monitoring the animal husbandry based on the German
Animal Welfare Act. Approval was given after careful inspection of the site
including bedding, feeding & water, ventilation, temperature, and humidity,
cleaning and hygiene concepts. Subcutaneous PDXs were established from 4 ×
4mm ccRCC tissue cubes in nude (Nu/J) mice and all subsequent experiments
were performed in NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NOD scid gamma)
mice. Specimens of ccRCC patients with distant metastases were used to enhance
engraftment efficiency14. Tumor growth was monitored for 3 months. Successfully
engrafted tumors were re-passaged and expanded for inhibitor treatment. Mice
were treated with 10 mg/kg DAPT i.p every 3 days or 100 mg/kg ICG-001, i.p. three
times a week. Tumor volumes were measured with a caliper. Mice were sacrificed
when control tumors reached 1 cm3 in volume.
Subcutaneous xenografts were harvested when tumors reached 1 cm3. Single
cells isolation and FACS was performed as described above. CXCR4+MET+CD44+
and CXCR4−MET−CD44−cells were diluted to appropriate concentrations and
injected orthotopically into the kidney parenchyma. Mice were observed for up to
3 month’s or until palpable tumors were formed in at least one group and
sacrificed. Kidneys were collected and analyzed for tumor formation.
Immunohistochemistry and immunofluorescence. Tissue samples were fixed in
10% neutral buffered formalin overnight at 4 °C, dehydrated, embedded in paraffin
and cut into 5 µM sections. Prior to staining, slides were rehydrated. For immu-
nohistochemistry, antigens were retrieved by boiling sections in Tris-EDTA buffer
(pH 9.0). Sections were incubated overnight at 4 °C with Ki-67 (1:200, Thermo
Fisher), NOTCH1 (1:200, Rockland Inc.), β-Catenin (1:500, Cell Signaling Tech-
nology), Calbindin (1:3000, Sigma Aldrich) primary antibodies and horseradish
peroxidase-conjugated secondary antibody. Staining was developed using the
Envision+ kit according to the manufacturer’s recommendations (Dako). Sections
were counterstained with eosin and photos were taken with an Axioscop (Zeiss)
and the Axiocam Hrc (Zeiss) using the Zen software (Zeiss). Ki-67 staining in
ccRCCs and xenografts was scored from 0 to 3, with 0 meaning no positive cells
and 3 meaning that the tumor cells were Ki-67 positive.
For immunofluorescence, antigens were retrieved by boiling sections in Tris-
EDTA buffer (pH 9.0). Section were incubated overnight at 4 °C with antibodies
against CA9 (1:200, Abcam), CD10 (1:30, Dako), CD44 (1:400, BD biosciences),
CXCR4 (1:200, Abcam), MET (1:50, Cell Signaling Technology), VCAM1 (1:250,
Abcam), E-Cadherin (1:1000, BD biosciences), Epcam (1:500, Abcam), Ki-67
(1:200, Thermo Fisher), or JAG1 (1:200, Atlas Antibodies) primary antibodies and
Alexa-conjugated secondary antibodies (1:200, Dianova). In case stainings were
performed with more than one antibody of the same host species, we used a
sequential protocol. Briefly, sections were incubated with primary antibodies o/n
followed by Alexa-conjugated secondary antibodies (1:250) for 1.5 h, then blocked
and incubated with the second set of primary antibodies o/n followed by the second
set of Alexa-conjugated secondary antibodies (1:200) for 30 min. To mark proximal
tubules, sections were incubated with biotinylated LTL (1:200, Vector laboratories)
at 4 °C overnight. Nuclei were counterstained with DAPI (100 ng/ml) and photos
were taken with an Axios Imager (Zeiss) and the Axiocam MRm (Zeiss) using the
Zen software (Zen). An overview of all antibodies in this study is provided in
Supplementary Table 6.
For PAS staining, slides were incubated 5 min in 0.5% periodic acid
followed by Schiff reagent for 20 min at RT. Sections were counterstained with
eosin. For hematoxylin-eosin (HE) staining, slides were incubated 2 min in
hematoxylin. Sections were counterstained with eosin fro 5 min. Photos were
taken with an Axioscop (Zeiss) and the Axiocam Hrc (Zeiss) using the Zen
software (Zeiss).
In situ hybridization. For in situ hybridization, Axin2 probe was linearized by SallI
and labeled using the DIG RNA Labeling Mix (Roche). Sections were rehydrated,
refixed, bleached, digested with proteinase K and acetylated with acetic anhydride.
Hybridization was performed o/n at 63 °C. Sections were blocked and incubated
with anti-DIG Fab (1:1000, Roche) o/n and stained with BM purple AP substrate
for 24 h.
Transmission electron microscopy (TEM). Organoids were fixed in 2% (w/v)
formaldehyde and 2.5% (v/v) glutaraldehyde in 0.1 M phosphate. After embedding
in 10% agarose, samples were post-fixed with 1% (v/v) osmium tetroxide, dehy-
drated in a graded series of EtOH, and embedded in PolyBed® 812 resin. Ultrathin
sections (60–80 nm) were stained with uranyl acetate as well as lead citrate and
examined at 80 kV with a Zeiss EM 910 electron microscope. Acquisition was done
with a Quemesa CCD camera and the iTEM software (Emsis GmbH).
Descriptive statistics, significance and power calculations. All statistical ana-
lyses were performed in GraphPad Prism (Graph Pad) and R unless stated
otherwise. D’Agostino and Pearson omnibus test, t-test or Mann–Whitney-U-test,
one-, RM, and two-way ANOVA with Tukey and Dunnett’s correction for mul-
tiple comparison, and Spearman correlation were used. IC50 were calculated by
non-linear regression analysis of the normalized response and the log of the
inhibitor concentration fitting a curve with a variable slope. All tests were per-
formed two-sided and a p-value < 0.05 was considered statistically significant.
Kaplan–Meyer and Cox regression analyses were performed in R and SPSS (IBM).
For xenograft assays, we estimated that we would need at least three samples per
treatment group to see a two-fold change in tumor volume, for a power of 80%
and for the probability of type I error (α)= 0.05. Power calculations were per-
formed in G*Power 3.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The Illumina bead chip experiments (data shown in Fig. 4, Supplementary Fig. 4, and
Supplementary Data 1) has been deposited in the Gene Expression omnibus under
accession number GSE89461, the gene expression data from fresh frozen ccRCC tissues
(data shown in Fig. 4 and Supplementary Fig. 4) is deposited under accession code
GSE66270 and GSE66271, the single-cell sequencing (data shown in Fig. 5 and
Supplementary Fig. 5) has been deposited under accession code GSE110680. All other
data is available in the Article, Supplementary Information or available from the authors
upon reasonable request.
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